Oral semaglutide adequate glycaemia control with safe cardiovascular ?profile

摘要

Background Type 2 diabetes is a chronic and progressive disease that ?associated with series complication such as major adverse ?cardiovascular events. Adequate glycaemic control proven ?to reduce this risk. Orally administered semaglutide ?promising medication in managing patient with type 2 ?diabetes.? Aims To assess the cardiovascular safety and efficacy of semaglutide, a recently approved glucagon-like peptide 1 receptor agonist (GLP-1 RA) for type 2 diabetes. Methods Pub Med, ?Google Scholar, and EBSCO ? databases were ?systematically search for relevant articles. The terms? diabetes?, Glucagon-like peptide, semaglutide? were used. Out of hundred twenty-two records, only ?four fulfilled ?the inclusion criteria. Results Four placebo-controlled studies with oral semaglutide ?were included. Single study concern about the cardiovascular safety of oral semaglutide ?and showed that, ?compared with placebo, semaglutide ? was not associated ?with increased in the cardiovascular events. On the other ?hand, the remaining trials shown that, semaglutide ? can ?effectively control the blood glucose as evident by ?reduction in HA1c. Conclusion Oral semaglutide can effectively and safely lower blood glucose without increase in the major adverse ?cardiovascular events?? (MACE).?